The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Respiratory Syncytial Virus Infections*/virology ; Respiratory Syncytial Virus Infections*/immunology ; Disease Models, Animal* ; Respiratory Syncytial Virus, Human*/physiology ; Respiratory Syncytial Virus, Human*/pathogenicity; Animals ; Humans ; Mice ; Sheep ; Respiratory Syncytial Virus Vaccines/immunology ; Respiratory Syncytial Virus Vaccines/administration & dosage ; Virus Replication ; Sigmodontinae/virology ; Respiratory Syncytial Viruses/immunology ; Respiratory Syncytial Viruses/physiology ; Primates

The development of immunoprophylactic products against respiratory syncytial virus (RSV) has resulted in notable advancements, leading to an increased demand for preclinical experiments and placing greater demands on animal models. Nevertheless, the field of RSV research continues to face the challenge of a lack of ideal animal models. Despite the demonstration of efficacy in animal studies, numerous RSV vaccine candidates have been unsuccessful in clinical trials, primarily due to the lack of suitable animal models. The most commonly utilized animal models for RSV research are cotton rats, mice, lambs, and non-human primates. These animals have been extensively employed in mechanistic studies and in the development and evaluation of vaccines and therapeutics. However, each model only exemplifies some, but not all, aspects of human RSV disease. The aim of this study was to provide a comprehensive summary of the disease symptoms, viral replication, pathological damage, and enhanced RSV disease (ERD) conditions across different RSV animal models. Furthermore, the advantages and disadvantages of each model are discussed, with the intention of providing a valuable reference for related RSV research.

Br J Pharmacol. 2021 Feb;178(3):515-530. (PMID: 33169387)
Sci Transl Med. 2021 Oct 20;13(616):eabj7843. (PMID: 34669442)
Chest. 1994 Jun;105(6):1848-54. (PMID: 8205887)
Viruses. 2012 Dec;4(12):3494-510. (PMID: 23342367)
Curr Top Microbiol Immunol. 2024;445:41-68. (PMID: 35704096)
J Infect Dis. 1993 Mar;167(3):553-61. (PMID: 8440926)
ILAR J. 2014;55(1):4-15. (PMID: 24936027)
J Infect Dis. 2013 Jul 15;208(2):319-29. (PMID: 23596321)
mSphere. 2021 May 12;6(3):. (PMID: 33980679)
Virol J. 2024 May 15;21(1):112. (PMID: 38750558)
PLoS Pathog. 2021 Apr 28;17(4):e1009529. (PMID: 33909707)
J Virol. 2013 Dec;87(23):12694-700. (PMID: 24049171)
PLoS One. 2013 Apr 18;8(4):e61309. (PMID: 23637810)
J Virol. 2017 Sep 12;91(19):. (PMID: 28747496)
Virol J. 2023 Feb 15;20(1):30. (PMID: 36793128)
Biomed Res Int. 2021 Sep 08;2021:9956078. (PMID: 34541002)
Arch Dis Child. 2003 Oct;88(10):922-6. (PMID: 14500316)
Int J Exp Pathol. 2009 Aug;90(4):431-8. (PMID: 19659901)
Vaccine. 1993 Nov;11(14):1395-404. (PMID: 8310760)
J Med Virol. 2022 Dec;94(12):5885-5893. (PMID: 35945613)
J Med Virol. 1988 Oct;26(2):153-62. (PMID: 3183639)
J Gen Virol. 2001 Nov;82(Pt 11):2663-2674. (PMID: 11602778)
Lancet. 2022 May 28;399(10340):2047-2064. (PMID: 35598608)
Vaccine. 2020 Jan 3;38(1):20-28. (PMID: 31672332)
Viruses. 2023 Nov 19;15(11):. (PMID: 38005952)
Am J Pathol. 1976 Feb;82(2):339-52. (PMID: 1251889)
Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H581-H589. (PMID: 29906223)
J Virol. 2016 Jul 27;90(16):7508-7518. (PMID: 27279612)
Am J Pathol. 1978 Dec;93(3):771-91. (PMID: 362946)
Zhonghua Er Ke Za Zhi. 2014 May;52(5):373-7. (PMID: 24969937)
EMBO J. 2019 Feb 15;38(4):. (PMID: 30643021)
J Virol. 2021 Jul 26;95(16):e0001021. (PMID: 34037420)
J Gen Virol. 2001 Dec;82(Pt 12):2881-2888. (PMID: 11714962)
Clin Vaccine Immunol. 2013 Feb;20(2):239-47. (PMID: 23239796)
Mucosal Immunol. 2019 Jul;12(4):969-979. (PMID: 31076663)
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14046-51. (PMID: 18780793)
Sci Rep. 2022 Oct 4;12(1):16579. (PMID: 36195733)
Front Microbiol. 2019 May 03;10:873. (PMID: 31130923)
PLoS One. 2019 Dec 2;14(12):e0225767. (PMID: 31790466)
Viruses. 2019 Jun 03;11(6):. (PMID: 31163619)
Nat Cell Biol. 2017 May;19(5):542-549. (PMID: 28436965)
Proc Soc Exp Biol Med. 1956 Jul;92(3):544-9. (PMID: 13359460)
J Med Chem. 2021 Apr 22;64(8):5001-5017. (PMID: 33835812)
MAbs. 2018 Jul;10(5):778-795. (PMID: 29733750)
Nature. 2020 Jul;583(7817):615-619. (PMID: 32494007)
Vaccine. 2017 Jan 11;35(3):469-480. (PMID: 27908639)
Viruses. 2022 Aug 09;14(8):. (PMID: 36016362)
PLoS Pathog. 2021 Dec 23;17(12):e1009856. (PMID: 34941963)
Hum Vaccin Immunother. 2022 Dec 30;18(7):2148499. (PMID: 36503354)
Am J Vet Res. 1979 Dec;40(12):1729-30. (PMID: 525890)
Microb Pathog. 2019 Dec;137:103749. (PMID: 31521801)
J Virol. 2015 Oct 07;90(1):2-4. (PMID: 26446604)
J Infect Dis. 1970 Dec;122(6):501-12. (PMID: 5489074)
Signal Transduct Target Ther. 2022 Jul 7;7(1):220. (PMID: 35798699)
J Virol. 2011 Jun;85(12):5782-93. (PMID: 21471228)
Clin Exp Immunol. 2004 Jul;137(1):139-45. (PMID: 15196254)
PLoS One. 2022 Mar 9;17(3):e0265094. (PMID: 35263387)
Vaccine. 2017 Jan 11;35(3):489-495. (PMID: 27889256)
J Neurochem. 2020 Sep;155(2):137-153. (PMID: 31811775)
STAR Protoc. 2022 Dec 16;3(4):101688. (PMID: 36116074)
Respir Res. 2011 Aug 09;12:106. (PMID: 21827668)
Curr Top Microbiol Immunol. 2013;372:371-87. (PMID: 24362700)
Lancet Infect Dis. 2023 Jan;23(1):e2-e21. (PMID: 35952703)
Eur Respir J. 1993 Oct;6(9):1324-31. (PMID: 8287949)
J Med Primatol. 2002 Apr;31(2):61-73. (PMID: 12110049)
J Infect Dis. 2007 Apr 15;195(8):1126-36. (PMID: 17357048)
Viruses. 2013 Nov 22;5(11):2881-97. (PMID: 24284879)
Infect Immun. 1984 Feb;43(2):649-55. (PMID: 6693171)
J Virol. 2004 Oct;78(20):11198-207. (PMID: 15452239)
Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L148-56. (PMID: 21571908)
Viruses. 2018 Jan 02;10(1):. (PMID: 29301313)
Expert Opin Drug Discov. 2022 Nov;17(11):1237-1259. (PMID: 36093605)
Virology. 2021 Nov;563:28-37. (PMID: 34411809)
PLoS One. 2020 Aug 10;15(8):e0237404. (PMID: 32776985)
Mod Pathol. 2007 Jan;20(1):108-19. (PMID: 17143259)
Proc Am Thorac Soc. 2005;2(2):166-73. (PMID: 16113487)
J Gen Virol. 2020 Oct;101(10):1056-1068. (PMID: 32723429)
Adv Virol. 2022 Mar 9;2022:8637545. (PMID: 35309598)
Vaccine. 2016 Jan 4;34(2):261-269. (PMID: 26616551)
J Virol. 2023 Jan 31;97(1):e0153622. (PMID: 36602361)
Animal Model Exp Med. 2022 Oct;5(5):401-409. (PMID: 36301011)
Science. 2013 May 31;340(6136):1113-7. (PMID: 23618766)
PLoS One. 2016 May 25;11(5):e0155777. (PMID: 27224021)
Viruses. 2022 Sep 20;14(10):. (PMID: 36298640)
Clin Microbiol Rev. 2017 Apr;30(2):481-502. (PMID: 28179378)
Trends Microbiol. 2013 May;21(5):238-44. (PMID: 23523320)
Science. 2022 Jan 14;375(6577):161-167. (PMID: 34855509)
J Virol. 1986 Mar;57(3):721-8. (PMID: 2419587)
N Engl J Med. 2023 Apr 20;388(16):1465-1477. (PMID: 37018468)
Vaccine. 2013 Jan 2;31(2):306-12. (PMID: 23153444)
PLoS One. 2021 Mar 11;16(3):e0235026. (PMID: 33705390)
J Infect Dis. 2004 May 15;189(10):1856-65. (PMID: 15122522)
Microbes Infect. 2004 Nov;6(14):1312-9. (PMID: 15555538)
Vaccine. 1990 Apr;8(2):164-8. (PMID: 2336876)
Curr Top Microbiol Immunol. 2013;372:359-69. (PMID: 24362699)
Biores Open Access. 2014 Apr 1;3(2):60-9. (PMID: 24804166)
PLoS One. 2015 Dec 07;10(12):e0143580. (PMID: 26641081)
Am J Epidemiol. 1969 Apr;89(4):422-34. (PMID: 4305198)
Viruses. 2023 Aug 30;15(9):. (PMID: 37766253)
Cell Tissue Res. 2020 May;380(2):313-324. (PMID: 32347384)
N Engl J Med. 2022 Jun 23;386(25):2377-2386. (PMID: 35731653)
J Virol. 2020 Dec 22;95(2):. (PMID: 33115876)
J Infect. 2024 Oct 9;89(6):106305. (PMID: 39389204)
Pediatr Dev Pathol. 1999 Jul-Aug;2(4):316-26. (PMID: 10347274)
JAMA. 2017 Jan 3;317(1):98. (PMID: 28030703)
Vaccine. 2015 Nov 25;33(47):6488-92. (PMID: 26319066)
mBio. 2022 Feb 15;13(1):e0351121. (PMID: 35164569)
Sci Adv. 2022 Jun 24;8(25):eabo2236. (PMID: 35749502)
Immunol Rev. 2011 Jan;239(1):149-66. (PMID: 21198670)
N Engl J Med. 2005 Apr 28;352(17):1749-59. (PMID: 15858184)
Adv Sci (Weinh). 2024 Mar;11(12):e2306729. (PMID: 38225749)
PLoS One. 2015 May 26;10(5):e0126959. (PMID: 26010881)
Eur Respir J. 1997 Jan;10(1):20-6. (PMID: 9032486)
Mol Ther. 2024 Apr 3;32(4):1033-1047. (PMID: 38341613)
Vaccine. 2017 Jul 13;35(32):3951-3958. (PMID: 28624306)
Respir Res. 2015 Aug 01;16:91. (PMID: 26231396)
J Virol. 2019 Mar 21;93(7):. (PMID: 30651356)
PLoS One. 2013 Dec 06;8(12):e81472. (PMID: 24324695)
PLoS Pathog. 2015 Mar 13;11(3):e1004757. (PMID: 25769044)
Am J Epidemiol. 1969 Apr;89(4):405-21. (PMID: 4305197)
N Engl J Med. 2023 Feb 16;388(7):595-608. (PMID: 36791160)
Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14. (PMID: 20622030)
Viruses. 2021 Aug 18;13(8):. (PMID: 34452495)
J Immunol. 2023 Oct 15;211(8):1180-1186. (PMID: 37782855)
J Med Virol. 1977;1(3):157-62. (PMID: 416176)

Grant No. 2022YFC2303404 National Key Research and Development Project of China; Grant No. 2022-I2M-1-020 CAMS Innovation Fund for Medical Sciences

Keywords: animal model; bronchiolitis; enhanced RSV disease (ERD); respiratory syncytial virus (RSV)

0 (Respiratory Syncytial Virus Vaccines)

Date Created: 20241127 Date Completed: 20241127 Latest Revision: 20241130

20241202

PMC11598872

10.3390/v16111701

39599816